The American Psychological Association (APA) recommends that all patients taking antipsychotic medication should be regularly screened for drug-induced movement disorders (DIMDs), including tardive dyskinesia (TD). Yet, despite known risks and significant impacts to patient quality of life, movement disorders may go unmonitored. Studies suggest that 70% of individuals with TD are undiagnosed. However, early screening and recognition of DIMDs can lead to better patient outcomes.

Watch to learn:

• Best practices for integrating the AIMS assessment into clinical practice in both behavioral health and primary care
• Strategies for behavioral health leaders and psychiatric clinicians to advocate for movement disorder monitoring within their medical groups or health systems
• The important role of primary care providers in detecting movement disorders
• How to leverage the electronic health record (EHR) to assist providers in identifying abnormal involuntary moments at the point of care